title: [Effect of DC therapy combined with chemotherapy in advanced cancer cases].
abstract: Dendritic cells (DC) are powerful antigen-presenting cells, and have attracted attention in recent years from the viewpoint of DC vaccine therapy against cancer. However, the existence of an immunosuppressive state in cancer individuals leads to anergy and immunotolerance, which has been reported to be caused by T cell and DC immunosuppressive subsets or cytokines such as Th2, Tc2, CD4+CD25+, DC2 and IL-10 against Th1, Tc1, DC1 and IL-12. Therefore, DC therapy could be incompatible with severe chemotherapy. Conversely, there are some reports that indicate tumor specific cytotoxicity in DC therapy could be augmentedly un exposure to tumor antigen caused by apoptosis in combination radiation or chemotherapy. In this study we examined the usefulness of DC therapy combined with chemotherapy and BRM (PSK) administration by analyzing the immunocyte subsets and cytokines as well as the combination effect. The results indicate this method can be useful in advanced cancer patients.
authors: Dept. of Surgery 2, Fukushima Medical University.
authors: Masashi
authors: M
authors: Kanazawa
authors: Yayoi
authors: Y
authors: Mori
authors: Kazue
authors: K
authors: Yoshihara
authors: Manabu
authors: M
authors: Iwadate
authors: Satoshi
authors: S
authors: Suzuki
authors: Yoshiyuki
authors: Y
authors: Endoh
authors: Ken-ichi
authors: K
authors: Takita
authors: Kouji
authors: K
authors: Sekikawa
authors: Seiichi
authors: S
authors: Takenoshita
authors: Takashi
authors: T
authors: Ogata
authors: Hitoshi
authors: H
authors: Ohto
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D015704:CD4 Antigens / Q000097:blood; D003110:Colonic Neoplasms / Q000276:immunology / Q000628:therapy*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood; D003713:Dendritic Cells / Q000637:transplantation*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D018664:Interleukin-12 / Q000097:blood; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation; D011509:Proteoglycans / Q000008:administration & dosage*; D015375:Receptors, Interleukin-2 / Q000097:blood; D013274:Stomach Neoplasms / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D015704:CD4 Antigens; D016207:Cytokines; D011509:Proteoglycans; D015375:Receptors, Interleukin-2; D016753:Interleukin-10; D018664:Interleukin-12; C010770:polysaccharide-K